Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer Seven-year results from the ...

Now four years into a first-in-class FDA approval for certain HR-positive, HER2-negative early breast cancers, Eli Lilly’s Verzenio has proven it can extend patients’ lives in the indication. Verzenio ...

Eli Lilly (NYSE:LLY) announced on Wednesday that its FDA-approved antitumor agent Verzenio, as part of a combination regimen, improved overall survival in a late-stage trial for certain patients with ...

Pharmaceutical advancements continue to reshape the landscape of cancer treatment, offering new hope for patients and altering market dynamics. Recent developments in innovative therapies demonstrate ...

The U.S. Food and Drug Administration has approved a new treatment for advanced breast cancer. Drugmaker Eli Lilly announced Sept. 25 the approval of Inluriyo, an oral estrogen receptor antagonist, to ...

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy for the next 2 years. On August 27, Eli Lilly and Company announced that its drug, Verzenio (abemaciclib), combined with ...

In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine ...

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year ...

News provided by Eli Lilly and Company Oct 17, 2025, 8:00 AM ET Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, ...